Gallocyanine
CAS No. : 524-26-5
(Synonyms: NCI8642)
Price and Availability of
CAS No. : 524-26-5
| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-124841 |
| M.Wt: | 300.27 |
| Formula: | C15H12N2O5 |
| Purity: | >98 % |
| Solubility: |
Introduction of
524-26-5
:
In Vitro:Gallocyanine (NCI8642) (1-10 μM) potently reverses DKK1-mediated inhibition of WNT3A-stimulated reporter gene activity in NIH 3T3 cells with an EC50 of ~5 μM[1].
Gallocyanine (0.1-100 μM) inhibits DKK1-AP binding to wild-type LRP5-expressing HEK293 cells with an IC50 of about 3 μM, without affecting binding to Kremen1-expressing cells[1].
Gallocyanine inhibits the binding of DKK2C to recombinant LRP6-E3E4 with an inhibition constant of 14 μM[1].
Gallocyanine (100 μM; 2 h) inhibits DKK1 binding to LRP6 in HEK-293LRP6 cells with an IC50 of 6.38 μM, reducing DKK1 binding to 47.8% at 100 μM[2].
Gallocyanine (10-100 μM; 24 h) is not cytotoxic to SH-SY5Y cells at concentrations up to 100 μM after 24 hours of incubation[2].
Gallocyanine (10 μM; 1 h) inhibits PGJ2-induced Tau phosphorylation at serine 396 in mouse primary cortical neurons, reducing phosphorylation levels to 55% at 10 μM[2].
Gallocyanine (0.1-10 μM; 1 h) dose-dependently inhibits DKK1-induced Tau phosphorylation at serine 396 in SH-SY5Y cells[2].
Gallocyanine (0.1-10 μM; 1 h) dose-dependently activates Wnt/β-catenin signaling in SH-SY5Y cells by increasing pGSK3β and β-catenin levels[2]. In Vivo:Gallocyanine (administered via local subcutaneous injection over the skull; three times daily for 5 consecutive days) promotes local new bone formation in the skull of 6-week-old CD-1 mice, and its effect in this local bone formation assay is comparable to that of the positive control b-FGF[1].
Gallocyanine (IIIC3; 3.5 or 7.0 mg/kg/day; intraperitoneal injection) exerts no obvious overall effect on whole-body bone mineral density (BMD) in mice, but the BMD of the 3.5 mg/kg/day group increases by approximately 3% at the end of the experiment[1].
Gallocyanine (IIIC3; i.p.) reduces blood glucose levels during routine toxicity monitoring in mice[1].
Gallocyanine (NCI8642) is a DKK/LRP interaction inhibitor and Wnt/β-catenin signaling pathway activator. Gallocyanine binds to the YWTD repeat domains of LRP5/6, competitively blocks the interaction between DKK and LRP5/6, with an IC50 of approximately 3 μM for inhibiting DKK1 binding to LRP5, an IC50 of 6.38 μM for inhibiting DKK1 binding to LRP6, and a Ki of 14 μM for inhibiting the DKK2C/LRP6-E3E4 interaction. Gallocyanine reverses the inhibitory effect of DKK1 on WNT3A signaling, with an EC50 of approximately 5 μM. Gallocyanine can be used in studies related to Alzheimer's disease, bone formation and glucose metabolism[1].
Gallocyanine (0.1-100 μM) inhibits DKK1-AP binding to wild-type LRP5-expressing HEK293 cells with an IC50 of about 3 μM, without affecting binding to Kremen1-expressing cells[1].
Gallocyanine inhibits the binding of DKK2C to recombinant LRP6-E3E4 with an inhibition constant of 14 μM[1].
Gallocyanine (100 μM; 2 h) inhibits DKK1 binding to LRP6 in HEK-293LRP6 cells with an IC50 of 6.38 μM, reducing DKK1 binding to 47.8% at 100 μM[2].
Gallocyanine (10-100 μM; 24 h) is not cytotoxic to SH-SY5Y cells at concentrations up to 100 μM after 24 hours of incubation[2].
Gallocyanine (10 μM; 1 h) inhibits PGJ2-induced Tau phosphorylation at serine 396 in mouse primary cortical neurons, reducing phosphorylation levels to 55% at 10 μM[2].
Gallocyanine (0.1-10 μM; 1 h) dose-dependently inhibits DKK1-induced Tau phosphorylation at serine 396 in SH-SY5Y cells[2].
Gallocyanine (0.1-10 μM; 1 h) dose-dependently activates Wnt/β-catenin signaling in SH-SY5Y cells by increasing pGSK3β and β-catenin levels[2]. In Vivo:Gallocyanine (administered via local subcutaneous injection over the skull; three times daily for 5 consecutive days) promotes local new bone formation in the skull of 6-week-old CD-1 mice, and its effect in this local bone formation assay is comparable to that of the positive control b-FGF[1].
Gallocyanine (IIIC3; 3.5 or 7.0 mg/kg/day; intraperitoneal injection) exerts no obvious overall effect on whole-body bone mineral density (BMD) in mice, but the BMD of the 3.5 mg/kg/day group increases by approximately 3% at the end of the experiment[1].
Gallocyanine (IIIC3; i.p.) reduces blood glucose levels during routine toxicity monitoring in mice[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Gallocyanine
- Cat. No.:
- HY-124841
- Quantity:
Your information is safe with us.